April 6th, 2012
By Paul Stoffels, MD, Worldwide Chairman, Pharmaceuticals
Each year on April 7th, the World Health Organization celebrates World Health Day. This year’s focus is on aging and health, which includes diseases and conditions that affect aging populations, such as Alzheimer’s disease. In recognition of that focus, I wanted to share some of the work that Johnson & Johnson is doing and the partnerships we are engaged in to make progress against this disease.
This is a critical time for people facing Alzheimer’s disease (AD). Approximately 31 million men and women worldwide have this devastating brain disease and estimated costs associated with treatment and care through 2050 are $20 trillion. Yet delaying the onset by as little as five years would reduce this cost to society by a third. The emotional toll of Alzheimer’s is devastating. AD is second only to cancer as the most feared health condition in the United States.
Progress in Alzheimer’s disease research during the past decade is culminating in a significant body of knowledge that could lead to earlier, more accurate detection of the disease and ways to slow its progression and possibly even prevent it. This scientific window of opportunity is prompting a diverse group of experts in AD to work together on unique ways to harness this new knowledge.